Financial Performance & Guidance - KORU Medical achieved Q1 2025 revenues of $9.6 million, representing an 18% increase year-over-year[8] - The company's core business experienced 21% growth, driven by recurring revenues, new patient starts, share expansion, and geographic expansion[8] - Gross margin improved to 62.8%, a 50 basis points increase[7] - KORU Medical raised its 2025 revenue guidance to $38.5-$39.5 million, projecting 15%-17% growth, and reaffirmed 61%-63% gross margins, with positive cash flow from operations expected for the full year[7] Strategic Growth & Market Expansion - Domestic core business revenue grew by 16% year-over-year[12] - International core business experienced 36% year-over-year growth[12] - Approximately 75% of KORU's revenue is recurring, excluding initial pump sales and Novel Therapies service revenue[15] Pipeline & Future Catalysts - KORU Medical plans to submit for FDA 510(k) clearance with 2 commercialized drugs on the Freedom Infusion System in 2025[8] - The company has 15 pharma collaborations in total, with 2 added year-to-date in 2025[13] - KORU Medical estimates its international market share at 10% with a goal of 30-40%[19]